~~17. A kit comprising:~~

~~(a) a first vessel containing a compound as defined in claim 1 or claim 13;~~
~~(b) a second vessel containing a substantially anhydrous solvent as defined in any one of claims 1-12.~~

~~18. The kit of claim 17, wherein the compound is in the form of a substantially anhydrous powder.~~

~~19. The kit of claim 18, wherein the compound is lyophilized.~~

~~20. The kit of any one of claims 17-19, wherein the first vessel contains about 80 mg to about 110 mg of said compound.~~

~~21. The kit of any one of claims 17-20, wherein the first vessel contains about 100 mg of said compound.~~

~~22. The kit of any one of claims 17-21, further comprising instructions for administration by subcutaneous injection.~~

~~23. The kit of any one of claims 18-22 wherein the substantially anhydrous powder consists essentially of said compound and DMSO, the DMSO being present in an amount of up to about 200 % w/w.~~

~~24. The kit of claim 23, wherein the DMSO is present in an amount of up to about 100%, up to about 60%, up to about 50%, up to about 40% or up to about 30% w/w DMSO/compound.~~

~~25. The kit of claim 24, wherein the DMSO is present in an amount of about 20 about 30% w/w DMSO/compound.~~

~~26~~17. A process for preparing a pharmaceutical composition comprising dissolving a compound as defined in claim 1 or claim 13 ~~or a substantially anhydrous powder as defined in claims 18 and 23-25~~ in a substantially anhydrous solvent as defined in any one of claims 1-12.

~~27~~18. The process of claim ~~26~~17, further comprising the steps of:

(a) dissolving said compound in DMSO to produce a solution of said compound in DMSO; and

(b) lyophilizing said solution of step (a) to provide said compound as a substantially anhydrous powder.

~~28. A pharmaceutical composition obtainable by the process of claim 26 or claim 27.~~

~~29~~19. The formulation of any one of claims 1-16~~, kit of any one of claims 17-25, or composition of claim 28~~ for use in treating a cancer, myelodysplastic syndrome, leukemia or solid tumour, wherein said formulation or composition is to be administered to a subject.

~~30~~20. Use of the formulation of any one of claims 1-16~~, kit of any one of claims 17-25, or composition of claim 28~~ for the manufacture of a medicament for treating a cancer, myelodysplastic syndrome, leukemia or solid tumour, wherein said medicament is to be administered to a subject.

~~31~~21. The formulation~~, composition, kit,~~ or use of claim ~~29~~ 9 or ~~30~~ 20 wherein the administration is subcutaneous administration.